PAVmed Provides Business Update and First Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Wall St slides as hot CPI data fuels rate-hike bets; chips, banks weigh
- Oil prices steady after gains on Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Canaccord Genuity Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
May 14, 2024 8:01 AM EDTCanaccord Genuity analyst Kyle Mikson reiterated a Buy rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD)
The analyst comments "We reiterate our BUY rating on Lucid Diagnostics (LUCD) shares and maintain our price target at $3. Before the market open on... More



